A Phase III Study of CS1001 in Combination With FP in Subjects With Esophageal Squamous Cell Carcinoma

Condition:   Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma Interventions:   Drug: CS1001+ Fluorouracil+Cisplatin;   Drug: Placebo+ Fluorouracil+Cisplatin Sponsor:   CStone Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials